Docoh
Loading...

21 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PRPO Precipio Inc
29 Apr 21
Definitive proxy
4:31pm
long-standing culture, which emphasizes incremental continuous improvement and sustained long-term stockholder value creation and ensures
424B5
PRPO Precipio Inc
2 Apr 21
Prospectus supplement for primary offering
2:00pm
or are paid by us for their diagnostic interpretation. Our Technology We have developed IV-Cell, a proprietary culture media that addresses the problem … We have developed IV-Cell, a proprietary culture media that addresses the problem of selective culturing – by creating a universal media that enables
10-K
2020 FY
PRPO Precipio Inc
29 Mar 21
Annual report
4:29pm
and reduce lengthy testing processes. Our Technology IV-CellTM IV-Cell is a proprietary cell culture media that addresses the problem of selective … . Hematopoietic Diseases: The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests
424B3
PRPO Precipio Inc
7 Jul 20
Prospectus supplement
5:27pm
-Cell We have developed IV-Cell, a proprietary culture media that addresses the problem of selective culturing – by creating a universal media … analysis by conducting cell-culture based tests by a cytogenetics laboratory to imitate in-vivo conditions. The four groups of cell lineages cultured
S-1
PRPO Precipio Inc
26 Jun 20
IPO registration
5:18pm
culture media that addresses the problem of selective culturing – by creating a universal media that enables simultaneous culturing of all 4 hematopoietic … during the culturing process. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests
DEF 14A
PRPO Precipio Inc
29 Apr 20
Definitive proxy
4:32pm
generally. The Compensation Committee considers the Company's long-standing culture, which emphasizes incremental continuous improvement and sustained long
424B3
PRPO Precipio Inc
13 Apr 20
Prospectus supplement
4:55pm
for their diagnostic interpretation. Our Technology IV-Cell We have developed IV-Cell, a proprietary culture media that addresses the problem of selective … of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests by a cytogenetics laboratory to imitate in-vivo conditions
S-3/A
PRPO Precipio Inc
9 Apr 20
Shelf registration (amended)
1:53pm
for their diagnostic interpretation. Our Technology We have developed IV-Cell, a proprietary culture media that addresses the problem of selective culturing … , a proprietary culture media that addresses the problem of selective culturing – by creating a universal media that enables simultaneous culturing of all 4
S-1/A
PRPO Precipio Inc
8 Apr 20
IPO registration (amended)
3:41pm
interpretation. Our Technology IV-Cell We have developed IV-Cell, a proprietary culture media that addresses the problem of selective culturing … of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests by a cytogenetics laboratory to imitate in-vivo conditions. The four
S-3
PRPO Precipio Inc
27 Mar 20
Shelf registration
4:51pm
interpretation. Our Technology We have developed IV-Cell, a proprietary culture media that addresses the problem of selective culturing – by creating … process, and the technician is able to select any of the 4 lineages during the culturing process. IV-Cell We have developed IV-Cell, a proprietary culture
S-1
PRPO Precipio Inc
27 Mar 20
IPO registration
4:31pm
Technology IV-Cell We have developed IV-Cell, a proprietary culture media that addresses the problem of selective culturing – by creating a universal … chromosomal analysis by conducting cell-culture based tests by a cytogenetics laboratory to imitate in-vivo conditions. The four groups of cell
10-K
2019 FY
PRPO Precipio Inc
27 Mar 20
Annual report
3:47pm
or are paid by us for their diagnostic interpretation. Our Technology IV-Cell We have developed IV-Cell, a proprietary culture media that addresses … . The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests by a cytogenetics laboratory
424B3
PRPO Precipio Inc
30 Jan 20
Prospectus supplement
5:09pm
for convenience upon 180 days’ prior written notice. IV-Cell The diagnostic process of hematopoietic diseases involves conducting cell-culture tests … . In most cases, due to specimen limitation, low cellularity, or cell viability, the cytogeneticist can select only one of the above cell lines to culture
S-1/A
PRPO Precipio Inc
27 Jan 20
IPO registration (amended)
4:47pm
written notice. IV-Cell The diagnostic process of hematopoietic diseases involves conducting cell-culture tests by the cytogenetic laboratory … to specimen limitation, low cellularity, or cell viability, the cytogeneticist can select only one of the above cell lines to culture. Often, the initial
S-1
PRPO Precipio Inc
14 Jan 20
IPO registration
4:26pm
of hematopoietic diseases involves conducting cell-culture tests by the cytogenetic laboratory to imitate in-vivo conditions. The four groups of cell … viability, the cytogeneticist can select only one of the above cell lines to culture. Often, the initial clinical suspicion is not in line with the final
424B3
PRPO Precipio Inc
21 Aug 19
Prospectus supplement
5:28pm
conducting cell-culture tests by the cytogenetic laboratory to imitate in-vivo conditions. The four groups of cell lineages cultured are: Myeloid cells … of the above cell lines to culture. Often, the initial clinical suspicion is not in line with the final diagnosis determined by the pathologist based
S-1
PRPO Precipio Inc
9 Aug 19
IPO registration
3:47pm
of hematopoietic diseases involves conducting cell-culture tests by the cytogenetic laboratory to imitate in-vivo conditions. The four groups of cell … viability, the cytogeneticist can select only one of the above cell lines to culture. Often, the initial clinical suspicion is not in line with the final
DEF 14A
PRPO Precipio Inc
29 Apr 19
Definitive proxy
5:22pm
. The Compensation Committee considers the Company's long-standing culture, which emphasizes incremental continuous improvement and sustained long-term shareholder
10-K
2018 FY
PRPO Precipio Inc
16 Apr 19
Annual report
5:20pm
. IV-Cell The diagnostic process of hematopoietic diseases involves conducting cell-culture tests by the cytogenetic laboratory to imitate in-vivo … , low cellularity, or cell viability, the cytogeneticist can select only one of the above cell lines to culture. Often, the initial clinical suspicion
8-K/A
EX-10.1
PRPO Precipio Inc
30 Jul 17
Entry into a Material Definitive Agreement
8:00pm
(FISH) 3 PM Next day Cytogenetics (Karyotype) Culture + 24 hours Flow cytometry with smears that are delivered by 12 pm will be due by 8 pm